ArticleBritish journal of cancer2021

A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer.

Benjamin C Creelan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.